Cowen analyst Yaron Werber assumed coverage on Bluebird Bio with an Outperform. The analyst believes that investors should have a strong interest in the stock, as bluebird has a deep pipeline, and is launching three drugs in 2019-2020, with “a slew of data” coming in 2019.
https://thefly.com/landingPageNews.php?id=2869859
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.